Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
75.8 USD | -0.14% | +4.93% | +2.16% |
May. 02 | Barclays Adjusts Price Target on Centene to $104 From $101 | MT |
Apr. 30 | Bernstein Adjusts Centene's Price Target to $94 From $100 | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.29 times its sales.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.16% | 40.5B | B- | ||
-4.55% | 461B | B- | ||
+13.07% | 125B | A- | ||
+15.96% | 98.49B | B- | ||
-29.27% | 39.12B | A- | ||
-4.10% | 20.5B | B- | ||
-13.10% | 3.18B | C+ | ||
-21.49% | 1.31B | B- | ||
-9.44% | 367M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CNC Stock
- Ratings Centene Corporation